Media stories about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 45.9190761868547 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- What’s the Competitive Landscape for Accelerate Diagnostics? (finance.yahoo.com)
- Thermo Fisher Scientific Inc. (NYSE:TMO) – Market Cap Evaluation – Nasdaq Journal (press release) (nasdaqjournal.com)
- Thermo Fisher – Fishing For Cash – Seeking Alpha (seekingalpha.com)
- Thermo Fisher Scientific (TMO) Cut to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Thermo Fisher Scientific Hits 80-Plus Relative Strength Rating Benchmark (finance.yahoo.com)
A number of equities research analysts have commented on the company. Zacks Investment Research cut Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a research note on Thursday. Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, October 26th. BTIG Research assumed coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. Leerink Swann increased their price target on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Finally, Evercore ISI assumed coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $212.21.
Shares of Thermo Fisher Scientific (NYSE TMO) traded up $1.51 during trading hours on Monday, hitting $210.17. The stock had a trading volume of 1,486,494 shares, compared to its average volume of 1,650,000. Thermo Fisher Scientific has a 1 year low of $140.00 and a 1 year high of $211.54. The stock has a market capitalization of $83,840.00, a PE ratio of 35.68, a price-to-earnings-growth ratio of 1.71 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same period last year, the business posted $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. research analysts expect that Thermo Fisher Scientific will post 9.36 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.29%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.
In other news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at $58,016,113.98. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific (TMO) Earns Coverage Optimism Rating of 0.12” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2018/01/15/thermo-fisher-scientific-tmo-earns-coverage-optimism-rating-of-0-12.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.